CASI CASI Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CASI

Price (delayed)

$5.59

Market cap

$74.78M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.01

Enterprise value

$54.81M

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is ...

Highlights
The debt has dropped by 100% year-on-year
CASI Pharmaceuticals's gross margin has increased by 9% YoY
CASI Pharmaceuticals's quick ratio has soared by 147% YoY but it has decreased by 7% from the previous quarter
CASI's gross profit is up by 25% YoY but it is down by 2.8% QoQ
CASI's EPS has dropped by 54% year-on-year
The equity has dropped by 53% year-on-year and by 11% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.casipharmaceuticals.com/
Peers: RGEN CRIS NBIX AMGN

Key stats

What are the main financial stats of CASI
Market
Shares outstanding
13.38M
Market cap
$74.78M
Enterprise value
$54.81M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.59
Price to sales (P/S)
1.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.3
Earnings
Revenue
$42.26M
EBIT
-$38.5M
EBITDA
N/A
Free cash flow
N/A
Per share
EPS
-$3.01
Free cash flow per share
N/A
Book value per share
$2.16
Revenue per share
$3.16
TBVPS
$5.53
Balance sheet
Total assets
$74.23M
Total liabilities
$23.79M
Debt
$0
Equity
$28.79M
Working capital
$46.29M
Liquidity
Debt to equity
0
Current ratio
4.91
Quick ratio
4
Net debt/EBITDA
N/A
Margins
EBITDA margin
N/A
Gross margin
63.8%
Net margin
-95.6%
Operating margin
-89.2%
Efficiency
Return on assets
-48%
Return on equity
-111.4%
Return on invested capital
-86.2%
Return on capital employed
-61.7%
Return on sales
-91.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CASI stock price

How has the CASI Pharmaceuticals stock price performed over time
Intraday
0%
1 week
-4.44%
1 month
18.43%
1 year
183.76%
YTD
212.29%
QTD
118.36%

Financial performance

How have CASI Pharmaceuticals's revenue and profit performed over time
Revenue
$42.26M
Gross profit
$26.98M
Operating income
-$37.7M
Net income
-$40.42M
Gross margin
63.8%
Net margin
-95.6%
CASI Pharmaceuticals's net income has decreased by 49% YoY
The net margin has declined by 31% year-on-year
CASI's gross profit is up by 25% YoY but it is down by 2.8% QoQ
The operating income has contracted by 15% YoY but it has grown by 2.8% from the previous quarter

Growth

What is CASI Pharmaceuticals's growth rate over time

Valuation

What is CASI Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.59
P/S
1.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.3
CASI's EPS has dropped by 54% year-on-year
The stock's P/B is 188% above its last 4 quarters average of 0.9 and 13% above its 5-year quarterly average of 2.3
The equity has dropped by 53% year-on-year and by 11% since the previous quarter
CASI's P/S is 153% above its last 4 quarters average of 0.7 but 91% below its 5-year quarterly average of 18.9
CASI's revenue is up by 14% YoY but it is down by 3.2% QoQ

Efficiency

How efficient is CASI Pharmaceuticals business performance
The return on equity has dropped by 196% year-on-year and by 21% since the previous quarter
CASI's ROIC has plunged by 131% YoY and by 10% from the previous quarter
The ROA has plunged by 129% YoY and by 14% from the previous quarter
CASI's return on sales is down by 26% year-on-year and by 2.2% since the previous quarter

Dividends

What is CASI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CASI.

Financial health

How did CASI Pharmaceuticals financials performed over time
CASI Pharmaceuticals's current ratio has soared by 163% YoY but it has decreased by 4.1% from the previous quarter
CASI Pharmaceuticals's quick ratio has soared by 147% YoY but it has decreased by 7% from the previous quarter
The debt is 100% smaller than the equity
CASI's debt to equity has shrunk by 100% YoY
The debt has dropped by 100% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.